BWX Technologies, Inc. (NYSE:BWXT) Given Consensus Rating of “Moderate Buy” by Analysts

BWX Technologies, Inc. (NYSE:BWXT) has been given an average rating of “Moderate Buy” by the thirteen analysts that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $200.45.

Several equities research analysts have commented on the stock. Zacks Research upgraded shares of BWX Technologies from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 21st. Truist Financial set a $205.00 price objective on BWX Technologies in a report on Friday, January 9th. BTIG Research raised their target price on BWX Technologies from $225.00 to $235.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. BNP Paribas Exane assumed coverage on BWX Technologies in a research note on Thursday, January 15th. They set a “neutral” rating and a $215.00 target price on the stock. Finally, Wall Street Zen lowered BWX Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th.

BWX Technologies Stock Down 2.3%

BWX Technologies stock opened at $195.86 on Wednesday. The company has a debt-to-equity ratio of 1.64, a quick ratio of 2.25 and a current ratio of 2.32. BWX Technologies has a one year low of $84.21 and a one year high of $220.57. The company has a 50-day simple moving average of $201.97 and a 200-day simple moving average of $189.26. The firm has a market capitalization of $17.91 billion, a P/E ratio of 54.86, a P/E/G ratio of 3.27 and a beta of 0.83.

BWX Technologies (NYSE:BWXT) last issued its quarterly earnings data on Monday, February 23rd. The technology company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.17. The firm had revenue of $885.84 million for the quarter, compared to the consensus estimate of $837.47 million. BWX Technologies had a net margin of 10.28% and a return on equity of 30.94%. BWX Technologies’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period last year, the firm posted $0.92 EPS. BWX Technologies has set its FY 2026 guidance at 4.550-4.700 EPS. As a group, equities analysts expect that BWX Technologies will post 3.23 earnings per share for the current year.

BWX Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 27th. Investors of record on Wednesday, March 11th will be paid a dividend of $0.27 per share. This is an increase from BWX Technologies’s previous quarterly dividend of $0.25. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Wednesday, March 11th. BWX Technologies’s dividend payout ratio (DPR) is presently 28.01%.

Insider Buying and Selling

In other BWX Technologies news, CAO Kevin James Gorman sold 1,344 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $214.71, for a total transaction of $288,570.24. Following the sale, the chief accounting officer directly owned 114 shares in the company, valued at approximately $24,476.94. The trade was a 92.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Rex D. Geveden sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $203.26, for a total transaction of $2,032,600.00. Following the completion of the sale, the chief executive officer directly owned 177,594 shares of the company’s stock, valued at approximately $36,097,756.44. This represents a 5.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 13,327 shares of company stock valued at $2,734,844 over the last 90 days. 0.47% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Artisan Partners Limited Partnership bought a new stake in BWX Technologies during the second quarter worth approximately $183,859,000. Alkeon Capital Management LLC boosted its stake in BWX Technologies by 163.0% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,578,048 shares of the technology company’s stock valued at $290,945,000 after purchasing an additional 978,000 shares in the last quarter. Invesco Ltd. increased its position in shares of BWX Technologies by 60.1% during the 3rd quarter. Invesco Ltd. now owns 2,549,150 shares of the technology company’s stock valued at $469,987,000 after purchasing an additional 956,770 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in shares of BWX Technologies during the 2nd quarter valued at $132,498,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of BWX Technologies in the 3rd quarter worth $163,969,000. 94.39% of the stock is currently owned by institutional investors.

About BWX Technologies

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non‐defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.